7:45-8:45 Registration/Breakfast for Workshop Participants
8:45-12:00 Workshop: Quantitative Deal Structure
The structure of collaborative business deals is critical for nearly all companies in the drug delivery industry. Yet many business development executives still structure these important agreements using only comparable business deals to guide them. A founding principle of any investment decision, such as structuring a collaborative deal, is the relationship between risk and return. Deal structures of higher risk should always have greater potential returns than structures of lower risk. In order to achieve this important relationship, decisions about the final financial terms of collaborative agreements should always be determined using specific valuation methods. This workshop will present the basic theory and most appropriate tools for business development executives to use in this important process.
Charles T. Hardy, PhD, MBA; President, Biovaluation & Analysis, Inc.
For more details, CLICK HERE
12:00-1:00 Lunch (for workshop participants)
12:15-1:00 Conference Registration
1:00-1:20 Chair’s opening remarks
Lewis H. Bender, President and CEO, Emisphere Technologies
1:20 Key Factors in Drug Delivery Success: Quantitative Assessment and Viable Business Models
This session will address key factors in drug delivery success including an examination of quantitative methods for assessing projects within the context of what makes a viable business model for drug delivery companies.
Questions answered in this session include:
Brian Gorin, Managing Principal, Analysis Group
2:00 Challenges and Opportunities in Oral Delivery of Macromolecules
Creating oral dosage forms of proteins and peptides would be a considerable breakthrough in the drug delivery industry. In the past 15 years several companies have come and gone trying to achieve this objective. Emisphere has advanced a number of compounds to Phase 3 and is considered the leader in the oral delivery of macromolecule field. Lewis H. Bender, Sr. Vice President of Business Development, has been at Emisphere for 15 years and will describe where the companies have stumbled in the past. Mr. Bender will also provide the criteria necessary for success.
Lewis H. Bender, President and CEO, Emisphere Technologies
2:40-3:15 Networking session (break)
3:15 Looking for Value in Partnering: How to Find the Right Technology, Market and Valuation
Every company is looking for partners. This process calls for in-depth analysis of four major areas to assess complementarities:
Dr. Lynnor Stevenson, Principal, Alta Biomedical Group
3:55 Novel Applications of Micellar Nanoparticles (MNPs)
This presentation will describe Novavax Pharmaceuticals’ proprietary Micellar Nanoparticle drug delivery technology. MNPs represent a composite vehicle that presents the drug in a variety of fractions: solubilized in the aqueous or hydro- alcoholic continuous phase, micellar solubilized form, associated with the oil fraction, and as surface-stabilized micro- /nano-crystals.
This session will explore MNPs potential within the context of:
Dr. Robert Lee, VP Pharma Development
4:35-5:15 Wine and cheese reception